Amgen (AMGN) Stock Price, Quote, News & History | Benzinga

Amgen Inc (AMGN) — Q1 FY26 Earnings Call Live coverage with Benzinga. Q1 FY26 Results EPS: $5.15 (est. $4.76) — inline Revenue: $8.62B (est. $8.55B) — inline Reported: 2026-04-30 Recent Quarters Q4 FY25 (2026-02-03): EPS $5.29 vs est $4.75 · Rev $9.87B vs est $9.46B Q3 FY25 (2025-11-04): EPS $5.64 vs est $5.01 · Rev $9.56B vs est $8.96B Q2 FY25 (2025-08-05): EPS $6.02 vs est $5.27 · Rev $9.18B vs est $8.89B Q1 FY25 (2025-05-01): EPS $4.90 vs est $4.30 · Rev $8.15B vs est $8.06B About Amgen Inc Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. https://www.amgen.com · Thousand Oaks, CA, USA · 31,500 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #AMGN #stocks #benzinga